Tutorials
NAS:CRSP (Switzerland)  
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

$ 78.66 +1.2 (+1.55%) 08:08 PM EST
P/E:
At Loss
P/B:
2.93
Market Cap:
$ 6.14B
Enterprise V:
$ 4.31B
Volume:
900.16K
Avg Vol (2M):
2.19M
Also Trade In:
Volume:
900.16K
Market Cap $:
6.14B
PE Ratio:
At Loss
Avg Vol (2-Month):
2.19M
Enterprise Value $:
4.31B
PB Ratio:
2.93
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

CRISPR Therapeutics AG
Baarerstrasse 14, Zug, CHE, CH-6300
Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Name Current Vs Industry Vs History
Cash-To-Debt 8.52
Equity-to-Asset 0.85
Debt-to-Equity 0.12
Debt-to-EBITDA -0.4
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.7
Distress
Grey
Safe
Beneish M-Score 10.6
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 52.67
9-Day RSI 52.76
14-Day RSI 53.88
6-1 Month Momentum % 33.08
12-1 Month Momentum % -41.61

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.57
Quick Ratio 17.57
Cash Ratio 17.22
Days Sales Outstanding 4.58
Days Payable 98.91

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -14.1

Financials (Next Earnings Date:2022-11-03 Est.)

CRSP's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:CRSP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 13.013
EPS (TTM) ($) -8.23
Beta 1.55
Volatility % 47.86
14-Day RSI 53.88
14-Day ATR ($) 5.17397
20-Day SMA ($) 78.2725
12-1 Month Momentum % -41.61
52-Week Range ($) 42.511 - 135.7028
Shares Outstanding (Mil) 78.01

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

CRISPR Therapeutics AG Filings

Document Form Filing Date
No Filing Data

Headlines

See More